EP0709099A3
(en)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
An aqueous nasal suspension comprising cyclodextrin
|
ZA959469B
(en)
*
|
1994-11-15 |
1996-05-15 |
South African Druggists Ltd |
Pharmaceutical composition
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
WO1996041646A2
(en)
*
|
1995-06-13 |
1996-12-27 |
Dyer, Alison, Margaret |
Pharmaceutical compositions containing lornoxicam and cyclodextrin
|
JP2000509374A
(en)
|
1996-04-19 |
2000-07-25 |
アルファ セラピュティック コーポレイション |
Method for virus inactivation of lyophilized blood proteins
|
UA57734C2
(en)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Arylheterocyclic inclusion complexes
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
DK0877600T3
(en)
*
|
1996-08-09 |
2004-02-02 |
Alcon Mfg Ltd |
Preservation system for pharmaceutical preparations containing cyclodextrin
|
DE19716120A1
(en)
*
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Use of cholesterol-lowering agents
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
EP0986403B1
(en)
*
|
1997-06-13 |
2003-11-12 |
Cydex Inc. |
Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
EP0889056B1
(en)
*
|
1997-07-01 |
2006-04-12 |
Pfizer Products Inc. |
Process for making a cyclodextrin
|
CA2306465A1
(en)
*
|
1997-11-07 |
1999-05-20 |
Daiichi Pharmaceutical Co. Ltd. |
Piperazine-cyclodextrin complexes
|
NZ505951A
(en)
*
|
1998-02-23 |
2003-02-28 |
Cyclops Ehf |
A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
EP1109581A1
(en)
*
|
1998-09-02 |
2001-06-27 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
FR2784584B1
(en)
*
|
1998-10-14 |
2002-09-20 |
Adir |
PROCESS FOR THE PREPARATION OF A NASAL SPRAY SOLUTION CONTAINING ONE OR MORE SEXUAL HORMONES AND A CYCLODEXTRIN
|
AU2162700A
(en)
*
|
1998-12-04 |
2000-06-26 |
California Institute Of Technology |
Supramolecular complexes containing therapeutic agents
|
US7375096B1
(en)
|
1998-12-04 |
2008-05-20 |
California Institute Of Technology |
Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
|
PL195280B1
(en)
|
1999-01-21 |
2007-08-31 |
Bristol Myers Squibb Co |
Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
WO2001030391A2
(en)
*
|
1999-10-27 |
2001-05-03 |
Farmarc Nederland Bv |
Pharmaceutical composition containing midazolam
|
US20030113367A1
(en)
*
|
2000-03-28 |
2003-06-19 |
Penkler Lawrence John |
Alprazolam inclusion complexes and pharmaceutical compositions thereof
|
EP1278549B1
(en)
*
|
2000-05-02 |
2008-12-10 |
Theravance, Inc. |
Composition containing a cyclodextrin and a glycopeptide antibiotic
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
ATE407134T1
(en)
|
2000-05-26 |
2008-09-15 |
Pfizer |
TRIAZOLYLTROPAND DERIVATIVES AS CCR5 MODULATORS
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
ATE356636T1
(en)
*
|
2000-08-03 |
2007-04-15 |
Antares Pharma Ipl Ag |
COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE INGREDIENTS WHICH GUARANTEES ADEQUATE THERAPEUTIC LEVELS
|
US7198801B2
(en)
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
PE20020300A1
(en)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(en)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
JP2005503446A
(en)
*
|
2001-01-11 |
2005-02-03 |
イーストマン ケミカル カンパニー |
Cyclodextrin sulfonate, guest inclusion complex, production method thereof and related substances
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
WO2002085860A1
(en)
|
2001-04-10 |
2002-10-31 |
Pfizer Limited |
Pyrazole derivatives for treating hiv
|
YU81503A
(en)
*
|
2001-05-01 |
2006-08-17 |
Pfizer Products Inc. |
method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(en)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
US7008934B2
(en)
*
|
2001-06-28 |
2006-03-07 |
Baxter International Inc. |
Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
|
CN1522159A
(en)
*
|
2001-06-29 |
2004-08-18 |
马克西根公司 |
Interferon formulations
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
PL365225A1
(en)
*
|
2001-07-20 |
2004-12-27 |
Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik |
Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
KR20040083493A
(en)
|
2002-02-01 |
2004-10-02 |
화이자 프로덕츠 인크. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
MXPA04007737A
(en)
|
2002-02-11 |
2004-10-15 |
Pfizer |
Nicotinamide derivatives useful as pde4 inhibitors.
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
JP2005521690A
(en)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
Ophthalmic preparations containing rubber
|
MXPA04008173A
(en)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride.
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
US6818662B2
(en)
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
GB0212749D0
(en)
*
|
2002-06-01 |
2002-07-10 |
Boots Co Plc |
Personal care compositions
|
DE60327225D1
(en)
*
|
2002-08-20 |
2009-05-28 |
Bristol Myers Squibb Co |
ARIPIPRAZOL COMPLEX FORMULATION AND METHOD
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
EP2277551B1
(en)
|
2002-09-06 |
2013-05-08 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
WO2004024126A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Cydex, Inc. |
Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
IL152573A
(en)
*
|
2002-10-31 |
2009-11-18 |
Transpharma Medical Ltd |
Transdermal delivery system for anti-emetic medication
|
IL152575A
(en)
*
|
2002-10-31 |
2008-12-29 |
Transpharma Medical Ltd |
Transdermal delivery system for water insoluble drugs
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
KR20090118994A
(en)
|
2002-12-13 |
2009-11-18 |
워너-램버트 캄파니 엘엘씨 |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
CA2513331A1
(en)
|
2003-01-14 |
2004-08-05 |
Teva Pharmaceutical Industries Ltd |
Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
|
JP4817068B2
(en)
*
|
2003-01-14 |
2011-11-16 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド |
Parenteral formulation of peptides for the treatment of systemic lupus erythematosus
|
EP1460064A1
(en)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide derivatives useful as beta-2 agonists
|
WO2004091630A1
(en)
*
|
2003-04-18 |
2004-10-28 |
Advanced Medicine Research Institute |
Remedies for diseases to be applied to eye
|
CL2004000826A1
(en)
|
2003-04-25 |
2005-03-04 |
Pfizer |
USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
PT1664036E
(en)
|
2003-09-03 |
2012-02-16 |
Pfizer |
Benzimidazolone compounds having 5-ht4 receptor agonistic activity
|
US7875630B2
(en)
|
2003-09-03 |
2011-01-25 |
Glaxo Group Limited |
Process salts compositions and use
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
KR100828218B1
(en)
|
2003-09-12 |
2008-05-07 |
화이자 인코포레이티드 |
Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-uptake inhibitors
|
ATE380813T1
(en)
|
2003-10-03 |
2007-12-15 |
Pfizer |
IMIDAZOPYRIDINE-SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONISTIC EFFECTS FOR THE TREATMENT OF HIV AND INFLAMMATION
|
PT1670433E
(en)
|
2003-10-10 |
2012-02-08 |
Ferring Bv |
Transdermal pharmaceutical formulation for minimizing skin residues
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
AU2004292445B2
(en)
|
2003-11-21 |
2010-02-04 |
Zalicus Inc. |
Methods and reagents for the treatment of inflammatory disorders
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
BRPI0418276B8
(en)
*
|
2003-12-31 |
2021-05-25 |
Cydex Pharmaceuticals Inc |
inhalable liquid formulation comprising budesonide
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
ME00557A
(en)
|
2004-01-22 |
2011-12-20 |
|
Sulfonamide derivatives for the treatment of diseases
|
ATE375977T1
(en)
|
2004-01-22 |
2007-11-15 |
Pfizer |
SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP1735284A1
(en)
|
2004-03-18 |
2006-12-27 |
Pfizer Limited |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
EP1730103B1
(en)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Formamide derivatives useful as adrenoceptor
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
WO2005105827A2
(en)
|
2004-04-15 |
2005-11-10 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
DK3520779T3
(en)
|
2004-04-23 |
2022-03-21 |
Cydex Pharmaceuticals Inc |
DPI formulation containing sulfoalkyl ether cyclodextrin
|
WO2005105763A1
(en)
|
2004-04-30 |
2005-11-10 |
Warner-Lambert Company Llc |
Substituted morpholine compounds for the treatment of central nervous system disorders
|
US20050250738A1
(en)
*
|
2004-05-06 |
2005-11-10 |
Mosher Gerold L |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
BRPI0510802A
(en)
*
|
2004-05-10 |
2007-11-06 |
Proteolix Inc |
enzyme inhibiting compounds
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
EP1758891A2
(en)
|
2004-06-15 |
2007-03-07 |
Pfizer Japan Inc. |
Benzimidazolone carboxylic acid derivatives
|
JP4084836B2
(en)
|
2004-08-12 |
2008-04-30 |
ファイザー・インク |
Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
|
BRPI0513915A
(en)
|
2004-08-26 |
2008-05-20 |
Pfizer |
enantiomerically pure aminoetheroaryl compounds as protein kinase inhibitors
|
ITMI20041763A1
(en)
*
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE
|
EP1809607B1
(en)
|
2004-11-02 |
2008-12-17 |
Pfizer, Inc. |
Sulfonyl benzimidazole derivatives
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(en)
*
|
2004-11-05 |
2006-10-27 |
|
PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM
|
US20060105992A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
US20060105045A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
PL2260835T3
(en)
*
|
2004-12-07 |
2013-08-30 |
Onyx Therapeutics Inc |
Composition for proteasome inhibition
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
CA2614223A1
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
WO2006097817A1
(en)
|
2005-03-17 |
2006-09-21 |
Pfizer Japan Inc. |
N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
|
DE602006003416D1
(en)
|
2005-03-21 |
2008-12-11 |
Pfizer Ltd |
SUBSTITUTED TRIAZONE DERIVATIVES AS OXYTOCINANTAGONISTS
|
DK1871353T3
(en)
*
|
2005-04-15 |
2011-04-04 |
Einstein Coll Med |
Vitamin K for the prevention or treatment of skin rash secondary to anti-EGFR therapy
|
US8076293B2
(en)
|
2005-04-19 |
2011-12-13 |
Gabriel Stavros Panayi |
Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption
|
WO2007124250A2
(en)
|
2006-04-21 |
2007-11-01 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
GT200600162A
(en)
*
|
2005-04-24 |
2007-03-14 |
|
METHODS TO MODULATE THE FUNCTION OF THE BLADDER
|
BRPI0611435A2
(en)
|
2005-05-04 |
2010-09-08 |
Pfizer Ltd |
2-starch-6-amino-8-oxopurine derivatives, pharmaceutical compositions, use and process for preparing same
|
CN101321742B
(en)
|
2005-05-26 |
2012-08-29 |
神经元系统公司 |
Compositions and methods of treating retinal disease
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
ATE456557T1
(en)
|
2005-06-15 |
2010-02-15 |
Pfizer Ltd |
SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITES
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
AR054849A1
(en)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
DE102005041860A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
|
ES2708375T3
(en)
|
2005-09-30 |
2019-04-09 |
Lundbeck Pharmaceuticals Llc |
New parenteral formulation of carbamazepine
|
US20100204178A1
(en)
*
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
BRPI0520654B8
(en)
|
2005-10-26 |
2021-05-25 |
Cydex Pharmaceuticals Inc |
sulfoalkyl ether cyclodextrin compositions and process for preparing the same
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
JP5436860B2
(en)
|
2005-11-09 |
2014-03-05 |
オニキス セラピューティクス, インク. |
Compounds for enzyme inhibition
|
US8022054B2
(en)
|
2005-11-28 |
2011-09-20 |
Marinus Pharmaceuticals |
Liquid ganaxolone formulations and methods for the making and use thereof
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
NL2000323C2
(en)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine derivatives.
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
JP2009520822A
(en)
*
|
2005-12-20 |
2009-05-28 |
ティカ レーケメデル アーベー |
Methods and systems for delivering corticosteroids
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
US20070191323A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Verus Pharmaceuticals, Inc. |
Stable corticosteroid mixtures
|
CL2007000774A1
(en)
*
|
2006-03-24 |
2008-03-07 |
Wyeth Corp |
USE OF COMPOUNDS DERIVED FROM CONDENSED DIAZEPIN TO TREAT URINARY INCONTINENCE.
|
KR20080105105A
(en)
*
|
2006-03-24 |
2008-12-03 |
와이어쓰 |
Methods for treating cognitive and other disorders
|
CL2007000775A1
(en)
*
|
2006-03-24 |
2008-01-25 |
Wyeth Corp |
Use of benzofuran-derived compounds for the treatment of a cognitive disorder.
|
CN101410112A
(en)
*
|
2006-03-24 |
2009-04-15 |
惠氏公司 |
New therapeutic combinations for the treatment of depression
|
MX2008012092A
(en)
*
|
2006-03-24 |
2008-10-03 |
Wyeth Corp |
Treatment of pain.
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
JP2009534388A
(en)
*
|
2006-04-18 |
2009-09-24 |
イーケーアール セラピューティクス, インク. |
Premix immediate use pharmaceutical formulation
|
CN100374468C
(en)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
Synthetic process for water soluble sulfoalkyl ether-beta-cyclic dextrine
|
US7691852B2
(en)
|
2006-06-19 |
2010-04-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
WO2008003317A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Genmab A/S |
Prevention of rash in patients undergoing anti-egfr therapy
|
AR061889A1
(en)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
IMPROVED PROCESS FOR THE PREPARATION OF VORICONAZOL
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
US20100022481A1
(en)
*
|
2006-08-02 |
2010-01-28 |
Dong Wang |
Drug Carriers, Their Synthesis, and Methods of Use Thereof
|
US20080207731A1
(en)
|
2006-08-23 |
2008-08-28 |
Intellect Neurosciences, Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20080194519A1
(en)
*
|
2006-09-15 |
2008-08-14 |
Regents Of The University Of Minnesota |
Topiramate compositions and methods for their use
|
EP2068853A2
(en)
|
2006-09-15 |
2009-06-17 |
Stevia APS |
Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo[3.2.1]octans such as steviol and isosteviol
|
WO2008035195A1
(en)
|
2006-09-21 |
2008-03-27 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
JP2010506839A
(en)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
Methods and compositions with reduced opalescence
|
NZ575624A
(en)
|
2006-10-18 |
2012-02-24 |
Pfizer Prod Inc |
Biaryl ether urea compounds
|
KR20090065537A
(en)
|
2006-10-20 |
2009-06-22 |
이코스 코포레이션 |
Compositions of chk1 inhibitors and cyclodextrin
|
CA2666539A1
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
US8158609B1
(en)
*
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
KR100822133B1
(en)
*
|
2006-11-06 |
2008-04-15 |
한미약품 주식회사 |
Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
|
BRPI0719096A2
(en)
*
|
2006-11-21 |
2013-12-03 |
Novartis Ag |
STABLE PARENTAL FORMULATION CONTAINING AN RSV INHIBITOR OF A BENZODIAZEPINA STRUCTURE
|
JP2010516625A
(en)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
Polymer-drug conjugates with tether groups for controlled drug delivery
|
ES2541454T3
(en)
|
2007-03-02 |
2015-07-20 |
Wyeth Llc |
Use of copper and glutamate in cell cultures for polypeptide production
|
EP2131849B1
(en)
*
|
2007-03-02 |
2011-10-26 |
The University Of Wollongong |
Compositions and methods for delivery of anti-cancer agents
|
ES2855700T3
(en)
*
|
2007-04-27 |
2021-09-24 |
Cydex Pharmaceuticals Inc |
Formulations containing clopidogrel and sulfoalkyl ether-cyclodextrin and methods of use
|
AU2015255164B2
(en)
*
|
2007-04-27 |
2017-06-08 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
JP2010527986A
(en)
*
|
2007-05-24 |
2010-08-19 |
ファイザー・リミテッド |
Spirocyclic quinazoline derivatives and their use as PDE7 inhibitors
|
EP2148692B1
(en)
|
2007-05-25 |
2017-01-25 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
ES2493641T3
(en)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Nasal administration of aqueous corticosteroid solutions
|
TWI428132B
(en)
*
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
Potentiation of cancer chemotherapy
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
KR100929920B1
(en)
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
Method for preparing clathrate containing hydrophobic physiologically active ingredient in cyclodextrin and derivatives thereof and use of clathrate prepared thereby
|
EP2215087B1
(en)
|
2007-09-05 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
|
CL2008002777A1
(en)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Method of preparing chiral diazepinoquinoline compounds by recrystallization in a ternary solvent system.
|
MY173938A
(en)
|
2007-10-04 |
2020-02-27 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2057982A1
(en)
*
|
2007-11-09 |
2009-05-13 |
Archimedes Development Limited |
Intranasal compositions
|
US8054177B2
(en)
*
|
2007-12-04 |
2011-11-08 |
Avaya Inc. |
Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
US20100022635A1
(en)
*
|
2008-07-28 |
2010-01-28 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
EP2328890B1
(en)
|
2008-08-06 |
2012-01-25 |
Pfizer Inc. |
6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
US20100093872A1
(en)
*
|
2008-10-15 |
2010-04-15 |
Erimos Pharmaceuticals Llc |
Stable aqueous formulations of water insoluble or poorly soluble drugs
|
KR20110073584A
(en)
|
2008-10-21 |
2011-06-29 |
오닉스 세라퓨틱스, 인크. |
Combination therapy with peptide epoxyketones
|
WO2010053487A1
(en)
|
2008-11-07 |
2010-05-14 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
CN104958296B
(en)
|
2008-11-15 |
2017-12-01 |
麦林塔医疗有限公司 |
Antimicrobial compositions
|
CA2741511C
(en)
|
2008-11-21 |
2017-01-24 |
Raqualia Pharma Inc. |
Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
ES2536191T3
(en)
|
2009-01-12 |
2015-05-21 |
Pfizer Limited |
Sulfonamide derivatives
|
PT2387580E
(en)
|
2009-01-14 |
2014-10-30 |
Novacta Biosystems Ltd |
Deoxyactagardine derivatives
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
JP5731407B2
(en)
|
2009-02-04 |
2015-06-10 |
ノヴァクタ バイオシステムズ リミティッド |
Actagardine derivatives
|
EP2406281B1
(en)
|
2009-03-12 |
2016-02-17 |
Haase Investments UG |
Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
|
AR075899A1
(en)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
PROTEASA INHIBITING CRYSTALLINE EPOXYCETON TRIPEPTIDES
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
EP3100728B1
(en)
*
|
2009-05-13 |
2019-11-20 |
Cydex Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
|
US20100311838A1
(en)
|
2009-05-29 |
2010-12-09 |
Pipkin James D |
Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
|
AU2010252609A1
(en)
|
2009-05-29 |
2011-11-10 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
RU2012101214A
(en)
|
2009-06-16 |
2013-07-27 |
Пфайзер Инк. |
DOSAGE FORMS OF APIKSABAN
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(en)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
MX2012007402A
(en)
|
2009-12-23 |
2012-08-23 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors.
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
KR101747476B1
(en)
|
2010-01-21 |
2017-06-14 |
드로브리지 파마슈티컬스 피티와이 엘티디 |
Anaesthetic formulation
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
US20120309676A1
(en)
|
2010-02-02 |
2012-12-06 |
Sjoerd Nicolaas Wadman |
Lantibiotic Salts
|
EP2539358A1
(en)
|
2010-02-25 |
2013-01-02 |
Pfizer Limited |
Peptide analogues
|
EP2542238B1
(en)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
EP3513660A1
(en)
*
|
2010-03-13 |
2019-07-24 |
Eastpond Laboratories Limited |
Fat-binding compositions
|
MX2012011604A
(en)
|
2010-04-07 |
2013-02-27 |
Onyx Therapeutics Inc |
Crystalline peptide epoxyketone immunoproteasome inhibitor.
|
CA2796967C
(en)
|
2010-05-04 |
2015-12-01 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
CN103037904B
(en)
|
2010-05-26 |
2015-04-22 |
纽柔菲克西亚有限公司 |
2-iminobiotin formulations and uses thereof
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
CN103079559A
(en)
*
|
2010-06-11 |
2013-05-01 |
巴克斯特国际公司 |
Formulations including amiodarone and salts thereof and methods of their manufacture and use
|
ES2526675T3
(en)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonylbenzamides as voltage dependent sodium channel inhibitors
|
EP2590951B1
(en)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
ES2532356T3
(en)
|
2010-07-09 |
2015-03-26 |
Pfizer Limited |
N-sulfonylbenzamides as voltage dependent sodium channel inhibitors
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
WO2012007868A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
JP2013531030A
(en)
|
2010-07-12 |
2013-08-01 |
ファイザー・リミテッド |
N-sulfonylbenzamide as an inhibitor of voltage-gated sodium channels
|
EP2593427B1
(en)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
WO2012025745A1
(en)
|
2010-08-24 |
2012-03-01 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
CA2816319C
(en)
|
2010-11-01 |
2020-06-30 |
Marshall Edwards, Inc. |
Isoflavonoid compounds and methods for the treatment of cancer
|
BR112013011991A2
(en)
|
2010-11-15 |
2016-08-30 |
Viiv Healthcare Uk Ltd |
compound, pharmaceutical composition, use of a compound, treatment method, product, and kit.
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
ES2672238T3
(en)
|
2011-01-26 |
2018-06-13 |
Allergan, Inc. |
Androgenic composition for the treatment of an ophthalmic condition
|
CN103384672B
(en)
|
2011-02-25 |
2016-09-28 |
武田药品工业株式会社 |
The substituted piperazine of N-pteridine and piperazine pteridinone
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
MX2013011612A
(en)
|
2011-04-05 |
2013-10-17 |
Pfizer Ltd |
Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases.
|
US9187463B2
(en)
|
2011-05-18 |
2015-11-17 |
Raqualia Pharma Inc. |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid
|
TWI544922B
(en)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
High concentration olopatadine ophthalmic composition
|
KR101731155B1
(en)
|
2011-06-15 |
2017-04-27 |
신톤 비.브이. |
Stabilized voriconazole composition
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
JP5898767B2
(en)
|
2011-07-13 |
2016-04-06 |
ファイザー・リミテッドPfizer Limited |
Enkephalin analog
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2739284A1
(en)
|
2011-08-02 |
2014-06-11 |
Pfizer Inc |
Crizotinib for use in the treatment of cancer
|
EP2739274A1
(en)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
RU2665571C2
(en)
|
2011-09-08 |
2018-08-31 |
Сейдж Терапьютикс, Инк. |
Neuroactive steroids, compositions and uses thereof
|
KR20140078619A
(en)
|
2011-09-18 |
2014-06-25 |
유로-셀띠끄 소시에떼 아노님 |
Pharmaceutical compositions
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
CN113234114A
(en)
|
2011-10-14 |
2021-08-10 |
萨奇治疗股份有限公司 |
3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof
|
JP5363636B2
(en)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
New salts and medical uses
|
MD20140037A2
(en)
|
2011-10-26 |
2014-08-31 |
Pfizer Limited |
(4-Phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators
|
CA2853231C
(en)
|
2011-10-28 |
2020-08-04 |
Inhibitaxin Limited |
Pyridazine derivatives with autotaxin activity for use in therapy
|
WO2013088315A1
(en)
|
2011-12-15 |
2013-06-20 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
TW201332572A
(en)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
Pharmaceutical preparation comprising substituted β -cyclodextrin
|
WO2013102826A1
(en)
|
2012-01-04 |
2013-07-11 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
AR092790A1
(en)
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
|
EP2809655B1
(en)
|
2012-02-03 |
2015-08-12 |
Pfizer Inc |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
TW201336527A
(en)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
Aqueous pharmaceutical composition with enhanced stability
|
DK3702374T3
(en)
|
2012-02-15 |
2022-06-27 |
Cydex Pharmaceuticals Inc |
PROCEDURE FOR MAKING CYCLODEXTRIN DERIVATIVES
|
RU2615385C2
(en)
|
2012-02-28 |
2017-04-04 |
Сидекс Фармасьютикалс, Инк. |
Alkylated cyclodextrin compositions and processes for preparing and using the same related applications
|
EP2822953B9
(en)
|
2012-03-06 |
2017-06-21 |
Pfizer Inc |
Macrocyclic derivatives for the treatment of proliferative diseases
|
WO2013148603A1
(en)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives as as btk inhibitors
|
DK2831122T3
(en)
|
2012-03-30 |
2016-05-17 |
Sapiotec Gmbh |
Anthocyanidin-complex
|
EP2869820A4
(en)
|
2012-07-09 |
2016-02-17 |
Onyx Therapeutics Inc |
Prodrugs of peptide epoxy ketone protease inhibitors
|
TW201414734A
(en)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
Azaindole derivatives
|
US20150216895A1
(en)
|
2012-08-03 |
2015-08-06 |
The United States of America, as represented by the Secretary, Department of Health & Human Servic |
Cyclodextrin for the treatment of lysosomal storage diseases
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
CA2884848C
(en)
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
WO2014053967A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
US20150258202A1
(en)
*
|
2012-10-17 |
2015-09-17 |
Sapiotec Gmbh |
Anthocyanidin complex for the treatment of multiple myeloma
|
EP2909239A4
(en)
|
2012-10-22 |
2016-06-08 |
Cydex Pharmaceuticals Inc |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
GEP201606598B
(en)
|
2012-11-08 |
2017-01-10 |
Pfizer |
Heteroaromatic compounds as dopamine d1 ligands
|
JP5857168B2
(en)
|
2012-11-08 |
2016-02-10 |
ファイザー・インク |
Heteroaromatic compounds as dopamine D1 ligands and their use
|
DK2919791T3
(en)
*
|
2012-11-15 |
2017-07-17 |
Sapiotec Gmbh |
Delphinidine complex as antiflogistic or immunosuppressant active substance
|
BR112015011392A2
(en)
|
2012-11-21 |
2017-07-11 |
Raqualia Pharma Inc |
polymorphic forms of acids, preparation process, pharmaceutical composition and use thereof
|
ES2609596T3
(en)
|
2012-12-03 |
2017-04-21 |
Pfizer Inc |
Novel androgen receptor selective modulators
|
EP2931286B1
(en)
*
|
2012-12-11 |
2017-10-04 |
SapioTec GmbH |
Delphinidin for combating melanoma cells
|
UA112028C2
(en)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
IMIDAZOPYRIDASINE DERIVATIVES AS HAMBA-RECEPTOR MODULATORS
|
UA111305C2
(en)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Condensed with lactams of aryl and heteroaryl
|
AU2014209387B2
(en)
|
2013-01-23 |
2018-11-01 |
Aldeyra Therapeutics, Inc. |
Toxic aldehyde related diseases and treatment
|
AU2014220354B2
(en)
|
2013-02-21 |
2018-02-01 |
Pfizer Inc. |
Solid forms of a selective CDK4/6 inhibitor
|
JO3377B1
(en)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
Pyridinyl and fused pyridinyl triazolone derivatives
|
RU2021111681A
(en)
|
2013-03-13 |
2021-05-11 |
Сейдж Терапьютикс, Инк. |
NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR APPLICATION
|
LT3461834T
(en)
|
2013-03-13 |
2021-10-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
HUE051403T2
(en)
|
2013-04-17 |
2021-03-01 |
Sage Therapeutics Inc |
19-nor neuroactive steroids for methods of treatment
|
CN113527400A
(en)
|
2013-04-17 |
2021-10-22 |
萨奇治疗股份有限公司 |
19-nor C3, 3-disubstituted C21-N-pyrazolylsterols and methods of use thereof
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201443025A
(en)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
Chemical compounds
|
TW201512171A
(en)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
Chemical compounds
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
HUE062265T2
(en)
|
2013-06-27 |
2023-10-28 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3019158A1
(en)
|
2013-07-08 |
2016-05-18 |
AbbVie Inc. |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
PT3021852T
(en)
|
2013-07-19 |
2021-04-21 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
WO2015027227A1
(en)
|
2013-08-23 |
2015-02-26 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(en)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
Macrocyclic compounds for the treatment of proliferative diseases
|
RU2572334C2
(en)
*
|
2013-12-06 |
2016-01-10 |
Общество С Ограниченной Ответственностью "Луфатен" |
Clathrate complex of arabinogalactan or arabic gum with 20-hydroxyecdysones, method for producing it (versions), pharmaceutical composition and medicinal product
|
US20170305857A1
(en)
|
2013-12-20 |
2017-10-26 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
US9371321B2
(en)
|
2014-01-09 |
2016-06-21 |
Astrazeneca Ab |
Azaindole derivatives
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN104971355B
(en)
*
|
2014-04-02 |
2018-04-24 |
上海现代药物制剂工程研究中心有限公司 |
Composition containing razaxaban and preparation method thereof
|
WO2015159175A1
(en)
|
2014-04-15 |
2015-10-22 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
CR20160494A
(en)
|
2014-04-25 |
2016-12-20 |
Pfizer |
HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE DIGINATES D1
|
AP2016009464A0
(en)
|
2014-04-25 |
2016-09-30 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
WO2015166370A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(en)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
Heterocyclic compounds and their use as dopamine D1 ligands
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
PE20161475A1
(en)
|
2014-05-14 |
2017-01-08 |
Pfizer |
PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES
|
WO2015173684A1
(en)
|
2014-05-15 |
2015-11-19 |
Pfizer Inc. |
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
|
ES2747989T3
(en)
|
2014-05-20 |
2020-03-12 |
Raqualia Pharma Inc |
Benzisoxazole derivative salt
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
HRP20221294T1
(en)
|
2014-05-29 |
2023-03-03 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions and uses thereof
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CA2950393A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
US9802945B2
(en)
|
2014-06-12 |
2017-10-31 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the GABAA receptor activity
|
JP6152495B1
(en)
|
2014-06-17 |
2017-06-21 |
ファイザー・インク |
Substituted dihydroisoquinolinone compounds
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
EP4306114A1
(en)
|
2014-06-18 |
2024-01-17 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
EP3166642B1
(en)
|
2014-06-18 |
2020-06-03 |
Audevard |
Transdermal formulations of pergolide and uses thereof
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
PT3183295T
(en)
|
2014-08-22 |
2023-11-03 |
Cydex Pharmaceuticals Inc |
Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
JOP20200195A1
(en)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016057713A1
(en)
|
2014-10-07 |
2016-04-14 |
Sage Therapeutics, Inc. |
Neuroactive compounds and methods of use thereof
|
NZ731095A
(en)
|
2014-10-16 |
2023-12-22 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
SG10202009861SA
(en)
|
2014-10-16 |
2020-11-27 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
SI3224269T1
(en)
|
2014-11-27 |
2020-10-30 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
TW201636342A
(en)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
Fumagillol derivatives
|
US9765000B2
(en)
|
2015-01-22 |
2017-09-19 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids, compositions and kits thereof
|
EP3050574B1
(en)
|
2015-01-28 |
2019-10-09 |
Universite De Bordeaux |
Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
|
WO2016126618A1
(en)
|
2015-02-02 |
2016-08-11 |
Mei Pharma, Inc. |
Combination therapies
|
EP4059522A1
(en)
|
2015-02-06 |
2022-09-21 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
DK3258939T3
(en)
|
2015-02-20 |
2022-12-12 |
Sage Therapeutics Inc |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
|
JP6584521B2
(en)
|
2015-02-24 |
2019-10-02 |
ファイザー・インク |
Substituted nucleoside derivatives useful as anticancer agents
|
WO2016148674A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates for treating diseases
|
EP3939582A1
(en)
|
2015-03-19 |
2022-01-19 |
Cydex Pharmaceuticals, Inc. |
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
|
WO2016164763A1
(en)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
KR20180035787A
(en)
|
2015-06-10 |
2018-04-06 |
브이테스, 인코포레이티드 |
Hydroxypropylbeta-cyclodextrin compositions and methods
|
CA2991311A1
(en)
|
2015-07-06 |
2017-01-12 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
DK3319611T3
(en)
|
2015-07-06 |
2021-04-12 |
Sage Therapeutics Inc |
OXYSTEROLS AND PROCEDURES FOR USE THEREOF
|
ES2884086T3
(en)
|
2015-07-06 |
2021-12-10 |
Sage Therapeutics Inc |
Oxysteroles and their procedures for use
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
TN2017000544A1
(en)
|
2015-07-31 |
2019-04-12 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
|
KR20180073554A
(en)
|
2015-08-21 |
2018-07-02 |
알데이라 테라퓨틱스, 아이엔씨. |
Deuterated compounds and uses thereof
|
EP3386983A1
(en)
|
2015-12-10 |
2018-10-17 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
DK3394045T3
(en)
|
2015-12-24 |
2021-08-16 |
Takeda Pharmaceuticals Co |
CO-CRYSTAL, MANUFACTURING PROCEDURE AND MEDICINE CONTAINING CO-CRYSTAL.
|
WO2017120429A1
(en)
|
2016-01-07 |
2017-07-13 |
CS Pharmasciences, Inc. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
AU2017208119B2
(en)
|
2016-01-15 |
2019-11-07 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
|
US20170239323A1
(en)
|
2016-02-18 |
2017-08-24 |
The Medicines Company |
Oritavancin formulations
|
US10426790B2
(en)
|
2016-02-28 |
2019-10-01 |
Aldeyra Therapeutics, Inc. |
Treatment of allergic eye conditions with cyclodextrins
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
WO2017173111A1
(en)
*
|
2016-03-31 |
2017-10-05 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
CN114272249A
(en)
|
2016-04-01 |
2022-04-05 |
萨奇治疗股份有限公司 |
Oxysterol and methods of use thereof
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
JP7116490B2
(en)
|
2016-05-09 |
2022-08-10 |
アルデイラ セラピューティクス, インコーポレイテッド |
Combined Treatment of Ocular Inflammatory Disorders and Diseases
|
US20190030170A1
(en)
*
|
2016-05-10 |
2019-01-31 |
Vireo Health LLC |
Cannabinoid formulations with improved solubility
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
WO2018009867A1
(en)
|
2016-07-07 |
2018-01-11 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN116162121A
(en)
|
2016-07-11 |
2023-05-26 |
萨奇治疗股份有限公司 |
C17, C20 and C21 substituted neuroactive steroids and methods of use thereof
|
EP3481844B1
(en)
|
2016-07-11 |
2024-04-17 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
AU2017304103A1
(en)
|
2016-07-29 |
2019-01-17 |
Pfizer Inc. |
Cyclic peptides as C5 a receptor antagonists
|
BR112019002538A2
(en)
|
2016-08-11 |
2019-05-21 |
Ovid Therapeutics Inc. |
use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
|
MX2019001849A
(en)
|
2016-08-15 |
2019-05-09 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors.
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
JP7149266B2
(en)
|
2016-09-30 |
2022-10-06 |
セージ セラピューティクス, インコーポレイテッド |
Methods as C7-Substituted Oxysterols and NMDA Modulators
|
US11266631B2
(en)
|
2016-10-11 |
2022-03-08 |
Purdue Pharmaceutical Products L.P. |
Hodgkin lymphoma therapy
|
KR102521573B1
(en)
|
2016-10-18 |
2023-04-14 |
세이지 테라퓨틱스, 인크. |
Oxysterols and methods of their use
|
IL266093B2
(en)
|
2016-10-18 |
2024-02-01 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
JP2019535722A
(en)
|
2016-11-18 |
2019-12-12 |
アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Novel formulations of amidine substituted beta-lactam compounds based on modified cyclodextrins and acidifying agents, their preparation and use as antibacterial pharmaceutical compositions
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
EP4252856A3
(en)
|
2016-12-20 |
2024-01-24 |
Oligomerix, Inc. |
Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
|
JP6778833B2
(en)
|
2017-01-20 |
2020-11-04 |
深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. |
(Hetero) arylamide compounds for suppressing kinase activity
|
EP3838897A3
(en)
|
2017-01-20 |
2021-07-07 |
Shenzhen TargetRx, Inc. |
(hetero)arylamide compound for inhibiting protein kinase activity
|
AU2018208846A1
(en)
|
2017-01-20 |
2019-07-25 |
Pfizer Inc. |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
KR20190097242A
(en)
|
2017-01-23 |
2019-08-20 |
화이자 인코포레이티드 |
Heterocyclic Spiro Compounds as MAGL Inhibitors
|
US11274164B2
(en)
|
2017-02-07 |
2022-03-15 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Method for the preparation of sulfobutylether beta cyclodextrin sodium
|
US10414732B2
(en)
|
2017-03-16 |
2019-09-17 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
DK3600312T3
(en)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
PIPERIDINYL AND PIPERAZINYL SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6
|
EP3608321B1
(en)
|
2017-04-01 |
2022-09-07 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
|
KR20190141244A
(en)
|
2017-05-03 |
2019-12-23 |
사이덱스 파마슈티칼스, 인크. |
Compositions Containing Cyclodextrins and Busulfans
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
JOP20180057A1
(en)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
Tetrahydropyridopyrazine modulators of gpr6
|
TWI799426B
(en)
|
2017-06-22 |
2023-04-21 |
英商克拉德夫製藥有限公司 |
Small molecule modulators of human sting
|
US11267806B2
(en)
|
2017-06-26 |
2022-03-08 |
Shenzhen Targetrx, Inc. |
Indazole compound for use in inhibiting kinase activity, composition and application thereof
|
EP3626241A4
(en)
|
2017-06-26 |
2020-05-27 |
Shenzhen Targetrx, Inc. |
N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
US11319323B2
(en)
|
2017-08-11 |
2022-05-03 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors
|
BR112020004047A2
(en)
|
2017-08-30 |
2020-09-01 |
Beijing Xuanyi Pharmasciences Co., Ltd |
cyclic dinucleotides as stimulators of interferon gene modulators
|
JP6985764B2
(en)
|
2017-08-30 |
2021-12-22 |
深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. |
Aminopyrimidine compounds, compositions containing this compound and their use
|
WO2019047826A1
(en)
|
2017-09-05 |
2019-03-14 |
博奥阿迪斯生物科技公司 |
Aromatic derivative, preparation method for same, and medical applications thereof
|
EP3681879A1
(en)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
TW201920108A
(en)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives
|
AU2018348174A1
(en)
|
2017-10-10 |
2020-04-23 |
Aldeyra Therapeutics, Inc. |
Treatment of inflammatory disorders
|
WO2019075362A1
(en)
|
2017-10-12 |
2019-04-18 |
Sage Therapeutics, Inc. |
Method of treating cns disorders with neurosteroids and gabaergic compounds
|
EP3720867A1
(en)
|
2017-12-08 |
2020-10-14 |
Sage Therapeutics, Inc. |
Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
|
US20210009613A1
(en)
|
2017-12-12 |
2021-01-14 |
Shenzhen Targetrx, Inc. |
Arylphosphine oxides for inhibiting kinase activity
|
EP3730503A4
(en)
|
2017-12-21 |
2021-05-05 |
Shenzhen TargetRx, Inc. |
Antiviral nucleoside reverse transcriptase inhibitor
|
WO2019120121A1
(en)
|
2017-12-21 |
2019-06-27 |
深圳市塔吉瑞生物医药有限公司 |
Diphenylaminopyrimidine compound for inhibiting kinase activity
|
WO2019120071A1
(en)
|
2017-12-21 |
2019-06-27 |
深圳市塔吉瑞生物医药有限公司 |
Novel antiviral nucleoside reverse transcriptase inhibitor
|
IL275562B1
(en)
|
2017-12-22 |
2024-03-01 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
MX2020006608A
(en)
|
2017-12-22 |
2020-11-06 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders.
|
US11718642B2
(en)
|
2018-01-12 |
2023-08-08 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
CA3089490A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(en)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
|
TW201942116A
(en)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
Tetrahydroquinazoline derivatives useful as anticancer agents
|
EP3759094A1
(en)
|
2018-03-01 |
2021-01-06 |
Takeda Pharmaceutical Company Limited |
Piperidinyl-3-(aryloxy)propanamides and propanoates
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
WO2019201194A1
(en)
|
2018-04-16 |
2019-10-24 |
深圳市塔吉瑞生物医药有限公司 |
Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
|
WO2019201131A1
(en)
|
2018-04-16 |
2019-10-24 |
深圳市塔吉瑞生物医药有限公司 |
Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
|
KR20230152182A
(en)
|
2018-04-26 |
2023-11-02 |
화이자 인코포레이티드 |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
JP2021525809A
(en)
|
2018-05-30 |
2021-09-27 |
コンバート ファーマシューティカルズ エス.エー. |
Prodrugs and their medical use
|
BR112020024301A2
(en)
|
2018-06-01 |
2021-02-23 |
Bayer Cropscience Lp |
stabilized fungicidal composition comprising cyclodextrin
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
US11840535B2
(en)
|
2018-07-02 |
2023-12-12 |
Shenzhen Targetrx, Inc. |
Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
|
WO2020011141A1
(en)
|
2018-07-12 |
2020-01-16 |
深圳市塔吉瑞生物医药有限公司 |
Diarylpyrazole compound, composition comprising same, and use thereof
|
CN110272426B
(en)
|
2018-07-17 |
2022-05-31 |
深圳市塔吉瑞生物医药有限公司 |
Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity
|
JP2021531287A
(en)
|
2018-07-19 |
2021-11-18 |
ファイザー・インク |
Heterocyclic spiro compound as a MAGL inhibitor
|
WO2020033344A1
(en)
|
2018-08-06 |
2020-02-13 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
CA3113462A1
(en)
|
2018-09-25 |
2020-04-02 |
Aldeyra Therapeutics, Inc. |
Formulations for treatment of dry eye disease
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
JP7352981B2
(en)
|
2018-10-10 |
2023-09-29 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
Dihydroimidazopyrazinone compounds, compositions containing the compounds and uses thereof
|
WO2020077255A1
(en)
|
2018-10-12 |
2020-04-16 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
JP2022505146A
(en)
|
2018-10-19 |
2022-01-14 |
セージ セラピューティクス, インコーポレイテッド |
9 (11) -Unsaturated neurostimulating steroids and how to use them
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
EP3886984A1
(en)
|
2018-11-29 |
2021-10-06 |
Pfizer Inc. |
Pyrazoles as modulators of hemoglobin
|
MA54594A
(en)
|
2018-12-05 |
2022-04-06 |
Sage Therapeutics Inc |
NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF
|
US20220017539A1
(en)
|
2018-12-06 |
2022-01-20 |
Shenzhen Targetrx, Inc. |
Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
CA3124371A1
(en)
|
2018-12-21 |
2020-06-25 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
EP3885346A4
(en)
|
2018-12-21 |
2022-01-12 |
Shenzhen TargetRx, Inc. |
Aminopyrimidine compound used for inhibiting activity of protein kinase
|
WO2020141224A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
WO2020150210A1
(en)
|
2019-01-14 |
2020-07-23 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Tetrazolone substituted steroids and use thereof
|
BR112021013019A2
(en)
|
2019-01-23 |
2021-09-14 |
Pfizer Inc. |
POLYMORPHIC FORM OF A MONOPHOSPHATE HYDRATE SALT OF A KNOWN TETRAHYDROISOQUINOLINE DERIVATIVE
|
CN113330000A
(en)
|
2019-01-31 |
2021-08-31 |
辉瑞公司 |
3-carbonylamino-5-cyclopentyl-1 FI-pyrrole compound having inhibitory activity against CDK2
|
US20220098204A1
(en)
|
2019-02-18 |
2022-03-31 |
Shenzhen Targetrx, Inc. |
Substituted fused aromatic ring derivative, composition and use thereof
|
EP3932908A4
(en)
|
2019-02-27 |
2022-11-16 |
Shenzhen TargetRx, Inc. |
Substituted pyrazole compounds, compositions containing same, and use thereof
|
AR118471A1
(en)
|
2019-03-22 |
2021-10-06 |
Takeda Pharmaceuticals Co |
DERIVATIVES OF PIRROL AND IMIDAZOLE FUSED WITH PYRIDINE AS INHIBITORS OF RIPK2
|
JP2022526917A
(en)
|
2019-03-26 |
2022-05-27 |
アルデイラ セラピューティクス, インコーポレイテッド |
Ophthalmic preparations and their use
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
PE20220425A1
(en)
|
2019-04-29 |
2022-03-29 |
Solent Therapeutics Llc |
3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS MRGX2 INHIBITORS
|
MX2021014515A
(en)
|
2019-05-31 |
2022-03-22 |
Sage Therapeutics Inc |
Neuroactive steroids and compositions thereof.
|
KR20220016225A
(en)
|
2019-06-06 |
2022-02-08 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
2,4,6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
|
EP3990469A1
(en)
|
2019-06-27 |
2022-05-04 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
TW202114696A
(en)
|
2019-06-27 |
2021-04-16 |
美商賽吉醫療公司 |
Compositions and methods for treating cns disorders
|
CN114729000A
(en)
|
2019-06-27 |
2022-07-08 |
萨奇治疗股份有限公司 |
Compounds for the treatment of CNS disorders
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
TW202116734A
(en)
|
2019-07-25 |
2021-05-01 |
印度商裘拉德製藥私人有限公司 |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
CN114555127A
(en)
|
2019-08-06 |
2022-05-27 |
L.E.A.F.控股集团公司 |
Method for preparing polyglutamated antifolates and use of compositions thereof
|
US20220306659A1
(en)
|
2019-08-23 |
2022-09-29 |
Beijing Tide Pharmaceutical Co., Ltd. |
Compound inhibiting and inducing degradation of egfr and alk
|
JP2022548602A
(en)
|
2019-09-16 |
2022-11-21 |
武田薬品工業株式会社 |
Azole-fused pyridazin-3(2H)-one derivatives
|
JP2022550297A
(en)
|
2019-09-25 |
2022-12-01 |
ファイザー・インク |
Heteropolycyclic modulators of STING (interferon gene stimulator)
|
BR112022005674A2
(en)
|
2019-09-26 |
2022-06-21 |
Shenzhen Targetrx Inc |
Substituted aromatic fused ring derivative and composition comprising the same, and use thereof
|
JP2023502889A
(en)
|
2019-11-01 |
2023-01-26 |
上海科技大学 |
EED INHIBITOR, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
|
MX2022006014A
(en)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating tuberous sclerosis complex.
|
EP4079735A4
(en)
|
2019-12-16 |
2024-01-03 |
Beijing Tide Pharmaceutical Co Ltd |
Compound for inhibiting and inducing degradation of egfr kinase
|
US20230122967A1
(en)
|
2020-01-17 |
2023-04-20 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
Novel compounds as inhibitors of pcsk9
|
KR20220141328A
(en)
|
2020-02-12 |
2022-10-19 |
큐라데브 파마 프라이버트 리미티드 |
Small molecule STING antagonists
|
AR121609A1
(en)
|
2020-03-18 |
2022-06-22 |
Sage Therapeutics Inc |
NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
|
AR121682A1
(en)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
N-(HETEROCYCLIL AND HETEROCYCLILALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS
|
AR121683A1
(en)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
N-HETEROARYLALKYL-2-(HETEROCYCLIL AND HETEROCYCLILMETHYL)ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS
|
JP2021167301A
(en)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
|
WO2021220185A1
(en)
|
2020-05-01 |
2021-11-04 |
Pfizer Inc. |
Azalactam compounds as hpk1 inhibitors
|
PE20231375A1
(en)
|
2020-05-04 |
2023-09-07 |
Takeda Pharmaceuticals Co |
N-(PIPERIDIN-4-IL)BENZAMIDE DERIVATIVES OF LUMINAL ACTION
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
EP4155307A4
(en)
|
2020-05-20 |
2023-09-13 |
Beijing Tide Pharmaceutical Co., Ltd. |
2,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitors
|
EP4172171A1
(en)
|
2020-06-24 |
2023-05-03 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
|
TW202214641A
(en)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2 mutation inhibitors
|
CN113929688A
(en)
|
2020-07-13 |
2022-01-14 |
北京泰德制药股份有限公司 |
Pyrazolopyrimidine compounds as ATR kinase inhibitors
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
EP4204093A1
(en)
|
2020-08-27 |
2023-07-05 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors
|
TW202229239A
(en)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors
|
KR20230124916A
(en)
|
2020-11-25 |
2023-08-28 |
세이지 테라퓨틱스, 인크. |
Compositions and methods for treating CNS disorders
|
US20220306641A1
(en)
|
2021-03-18 |
2022-09-29 |
Pfizer Inc. |
Modulators of STING (Stimulator of Interferon Genes)
|
CA3213593A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
EP4320121A2
(en)
|
2021-04-07 |
2024-02-14 |
LifeArc |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
US11649299B2
(en)
|
2021-06-10 |
2023-05-16 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Purification of sulfobutylated cyclodextrins with specific ion exchange resins
|
AU2022297733A1
(en)
|
2021-06-26 |
2024-01-04 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023009584A1
(en)
|
2021-07-28 |
2023-02-02 |
Sage Therapeutics, Inc. |
Crystalline forms of a neuroactive steroid
|
CA3228653A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule urea derivatives as sting antagonists
|
CA3228528A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule sting antagonists
|
WO2023049295A1
(en)
|
2021-09-22 |
2023-03-30 |
Sage Therapeutics, Inc. |
Deuterated positive nmda-modulating compounds and methods of use thereof
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023144692A1
(en)
*
|
2022-01-25 |
2023-08-03 |
Leiutis Pharmaceuticals Llp |
Novel naproxen sodium preparations for parenteral
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(en)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
Fused pyridazine derivatives
|
WO2023205165A1
(en)
*
|
2022-04-22 |
2023-10-26 |
Brii Biosciences Offshore Limited |
A polymyxin composition and methods for producing the same
|
CN116969851A
(en)
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
Ionizable lipid compounds
|
EP4332087A1
(en)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid nanoparticles
|
WO2024026337A1
(en)
|
2022-07-27 |
2024-02-01 |
Sage Therapeutics, Inc. |
Crystalline forms of a neuroactive steroid
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024059608A1
(en)
|
2022-09-15 |
2024-03-21 |
Sage Therapeutics, Inc. |
Deuterated neuroactive steroids
|